The DNA printing technology received backing from investors including Merck Group, Illumina, Danaher and Agilent to hike its total funding to $280m.

France-based synthetic DNA producer DNA Script secured $165m in a series C round featuring corporates Merck Group, Illumina, Danaher and Agilent Technologies yesterday.

Coatue Management and Catalio Capital Management co-led the round, which included investment and financial services group Fidelity and Alexandria Venture Investments, part of life sciences real estate investment trust Alexandria Real Estate Equities.

BPIfrance’s Large Venture Fund made up the rest of the investors along with Arrowmark Partners, Farallon Capital, Columbia Threadneedle Investments, Moore Strategic Ventures, LSP,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn